Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

After hours: March 12 at 7:50:22 PM EDT Loading Chart for BLRX ...

This early unblinding will involve 30 participants receiving the combination of annamycin and cytarabine ... gains approval for enrolment in trial of AML therapy in Ukraine" was originally ...

Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are blood cell cancers that start in the bone marrow. AML is more common and more aggressive than CML. AML is usually treated with ...

allowing a reduced Phase 3 trial size for Annamycin with Cytarabine also known as AnnAraC in treating R/R AML patients. The global "MIRACLE" trial will span the US, Europe, and the Middle East.

Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia, in addition to Orphan Drug Designation for ...